MetaboMed, an Israel-based biopharmaceutical company, has named Ali Fattaey, PhD as its new CEO, it was reported on Wednesday.
The new CEO has more than 20 years of experience in private and public biotech executive management roles focused on cancer drug discovery and development.
Dr Fattaey has held the position of president and chief executive officer of Curis Inc. He has successfully raised funds in the private venture and public markets, hired and built cancer drug development teams, as well as set up strategic partnerships and collaborations within the industry.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer